Click Here for 5% Off Your First Aladdin Purchase!

MRE-269 (ACT-333679) - 98%, high purity , CAS No.475085-57-5, Agonist of EP 2 receptor;Agonist of EP 4 receptor;Agonist of IP receptor

  • Moligand™
  • ≥98%
Item Number
M413342
Grouped product items
SKUSizeAvailabilityPrice Qty
M413342-5mg
5mg
In stock
$58.90
M413342-10mg
10mg
In stock
$107.90
M413342-25mg
25mg
In stock
$243.90
M413342-50mg
50mg
In stock
$246.90
M413342-100mg
100mg
In stock
$444.90

Prostaglandin Receptor Agonists

Basic Description

SynonymsMRE-269|475085-57-5|ACT-333679|MRE269|MRE 269|ACT 333679|(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid|2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid|E9PC7N0DID|CHEMBL239226|ACT333679|2-[4-[(5,6-diphenylpyrazin-2-y
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsMRE-269 (ACT-333679) is a prostaglandin I2 (IP) receptor agonist with a binding affinity for the human IP receptor that is 130-fold greater than that for other human prostanoid receptor.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of EP 2 receptor;Agonist of EP 4 receptor;Agonist of IP receptor

Names and Identifiers

Pubchem Sid488196445
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488196445
IUPAC Name 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid
INCHI InChI=1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChi Key OJQMKCBWYCWFPU-UHFFFAOYSA-N
Canonical SMILES CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Isomeric SMILES CC(C)N(CCCCOCC(=O)O)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
PubChem CID 9931891
Molecular Weight 419.52

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
D23181196Certificate of AnalysisMar 11, 2023 M413342
D23181208Certificate of AnalysisMar 11, 2023 M413342
D23181213Certificate of AnalysisMar 11, 2023 M413342
D23181217Certificate of AnalysisMar 11, 2023 M413342
D23181226Certificate of AnalysisMar 11, 2023 M413342
D23181253Certificate of AnalysisMar 11, 2023 M413342
D23181309Certificate of AnalysisMar 11, 2023 M413342
D23181324Certificate of AnalysisMar 11, 2023 M413342
D23181327Certificate of AnalysisMar 11, 2023 M413342
D23181329Certificate of AnalysisMar 11, 2023 M413342

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 84 mg/mL (200.22 mM); Water: Insoluble; Ethanol: Insoluble;

Related Documents

References

1. Asaki T, Hamamoto T, Sugiyama Y, Kuwano K, Kuwabara K.  (2007)  Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists..  Bioorg Med Chem,  15  (21): (6692-704).  [PMID:17764960]
2. Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.  (2017)  Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential..  J Pharmacol Exp Ther,  362  (1): (186-199).  [PMID:28476928]

Solution Calculators